The present invention relates to a product comprising a PDE1 inhibitor and a PDE2 inhibitor, in free or salt form, pharmaceutical compositions comprising them and their use as pharmaceuticals for the treatment of cAMP and/or cGMP related disorders.

Synergistic herbal compositions for Testosterone boosting comprising at least two ingredients selected from the extracts, fractions or pure phytochemicals derived from Punica granatum, Cinnamomum zeylanicum, Nigella sativa, Brassica nigra and Mangifera indica for improving testosterone levels and alleviating symptoms associated with low levels of testosterone hormone in humans. The present invention also describes a synergistic composition comprising at least one testosterone booster ingredient selected from the extracts, fractions or pure phytochemical derived from Punica granatum, Cinnamomum zeylanicum, Nigella sativa, Brassica nigra and Mangifera indica and at least one aromatase inhibitor ingredient selected from the extracts, fractions or pure phytochemicals derived from Allium cepa, Tamarindus indica and Cinnamomum tamala for improving testosterone levels and alleviating symptoms associated with low levels of testosterone hormone in humans. The invention further provides methods of improving testosterone levels and alleviating symptoms associated with low levels of testosterone hormone in humans.

Synergistic herbal compositions for Testosterone boosting comprising at least two ingredients selected from the extracts, fractions or pure phytochemicals derived from Punica granatum, Cinnamomum zeylanicum, Nigella sativa, Brassica nigra and Mangifera indica for improving testosterone levels and alleviating symptoms associated with low levels of testosterone hormone in humans. The present invention also describes a synergistic composition comprising at least one testosterone booster ingredient selected from the extracts, fractions or pure phytochemical derived from Punica granatum, Cinnamomum zeylanicum, Nigella sativa, Brassica nigra and Mangifera indica and at least one aromatase inhibitor ingredient selected from the extracts, fractions or pure phytochemicals derived from Allium cepa, Tamarindus indica and Cinnamomum tamala for improving testosterone levels and alleviating symptoms associated with low levels of testosterone hormone in humans. The invention further provides methods of improving testosterone levels and alleviating symptoms associated with low levels of testosterone hormone in humans.

The invention relates to methods for preventing cancer in a KRAS-variant subject which include administering to the KRAS-variant subject an amount of estrogen effective to reduce the risk of developing cancer. In another aspect, the invention further relates to methods for treating cancer in a KRAS-variant subject, which include gradually decreasing estrogen exposure in the KRAS-variant subject to reduce the risk of aggressive tumor growth. In another aspect, the invention relates to a method of predicting an increased risk of developing a second, independent breast cancer in a subject. The method can include detecting a single nucleotide polymorphism (SNP) at position 4 of the let-7 complementary site 6 of KRAS in a patient sample wherein the presence of said SNP indicates an increased risk of developing a second, independent cancer in said subject.

The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.

##STR00001##

Novel compounds of Formula I ##STR00001##
and their use in therapeutic treatments.

The Basic Mix or Mix 1 or Mix 2 comprises of a combination of a Vitamin C (Ca ascorbate) 10 mg-100,000 mg, Vitamin E (D-alpha-tocopherol) 1 mg-3,000 mg, Vitamin B5 1 mg-20,000 mg, Vitamin B6 1 mg-1,000 mg, Folic acid 1 mcg-3,000 mcg, Iodine (Kelp) 1 mcg-2,000 mcg, Selenium 1 mcg-2,000 mcg, Choline 1 mg-5,000 mg, Inositol 1 mg-5000 mg, Phosphatidyl serine 1 mg-1,500 mg, Soy extract containing Daidzein 1 mg-1,500 mg, Glycitein 0.1 mg-1,000 mg, and Genistein 1 mg-2,500 mg, Red clover 1 mg-1,500 mg, Rosemary extract 1 mg-6,000 mg and Chaste tree berry (Vitex agnus-castus) 1 mg-2,000 mg. Mix 1 is effective in repressing the transcription of ApoE gene in fibroblast cells. The formulations counters specific pathology markers, alleviates markers associated with increased risk of degenerative problems (i.e. Alzheimer's disease).

Provided herein is an optimized method of enhancing endogenous gonadotropins and testosterone/estrogen production and concentrations comprising administration of a therapeutically effective amount of at least one GnRH agonist to a patient in need of such treatment. A method and dosing regimen is also described for delivery across the mucosa of the oral cavity for maximizing absorption and delivery, limiting systemic exposure and unwanted side effects, effectuating a sustained increase in concentrations of sex hormones and providing a non-invasive delivery that does not require inpatient visits. The method described benefits conditions such as hypogonadism in men due to aging or disease and symptoms related to menopause in women.

Disclosed herein are methods and compositions for treating or preventing ovarian failure using fibroblasts or cells derived from fibroblasts. In some embodiments, ovarian failure is pathological, the result of an intervention, or the result of aging. In some embodiments, regenerative fibroblast cells are administered locally into the ovary or pen-ovary areas or systemically. In some embodiments, regenerative cells act to suppress fibrosis of the ovaries, inhibit inflammation, stimulate maturation of immature ovarian progenitor cells, or directly differentiate into oocytes. In some embodiments, regenerative fibroblasts produce factors that inhibit apoptosis of oocytes and/or oocyte progenitors.